The Effects of Eicosapentaenoic Acid (EPA)/ Docosahexaenoic Acid (DHA) Supplementation on Cognitive Control in Children With Attention Deficit Hyperactivity Disorder (ADHD)
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Eicosapentaenoic acid/docosahexaenoic acid (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- 11 Dec 2013 Biomarkers information updated
- 30 Nov 2012 Planned End Date (1 May 2013) as reported by ClinicalTrials.gov.
- 30 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.